Literature DB >> 15703646

Cholestatic syndromes.

Michael Trauner1, James L Boyer.   

Abstract

PURPOSE OF REVIEW: This review highlights recent developments in the molecular pathogenesis of cholestasis as well new aspects of pathogenesis and management of clinical cholestatic disorders. RECENT
FINDINGS: Highlights include the role of nuclear receptors including FXR ligands as potential therapeutic agents, new genetic defects for pediatric cholestasis and sclerosing cholangitis, and novel infections and environmental agents as etiologies for primary biliary cirrhosis. Important clinical studies have been published in the area of pediatric cholestatic syndromes, intrahepatic cholestasis of pregnancy, primary biliary cirrhosis, primary and secondary sclerosing cholangitis, cholestasis of sepsis, viral cholestatic syndromes, and drug-induced cholestasis.
SUMMARY: These advances continue to improve understanding of the pathophysiology, diagnosis, and management of cholestatic liver disease.

Entities:  

Year:  2004        PMID: 15703646     DOI: 10.1097/00001574-200405000-00006

Source DB:  PubMed          Journal:  Curr Opin Gastroenterol        ISSN: 0267-1379            Impact factor:   3.287


  7 in total

Review 1.  FXR and PXR: potential therapeutic targets in cholestasis.

Authors:  Johan W Jonker; Christopher Liddle; Michael Downes
Journal:  J Steroid Biochem Mol Biol       Date:  2011-07-20       Impact factor: 4.292

2.  Radixin is required to maintain apical canalicular membrane structure and function in rat hepatocytes.

Authors:  Wei Wang; Carol J Soroka; Albert Mennone; Christoph Rahner; Kathy Harry; Marc Pypaert; James L Boyer
Journal:  Gastroenterology       Date:  2006-09       Impact factor: 22.682

3.  Prolonged cholestasis following successful removal of common bile duct stones: beware patients on estrogen therapy.

Authors:  J M Dunn; A McNair
Journal:  World J Gastroenterol       Date:  2007-12-14       Impact factor: 5.742

4.  Critical role of RanBP2-mediated SUMOylation of Small Heterodimer Partner in maintaining bile acid homeostasis.

Authors:  Dong-Hyun Kim; Sanghoon Kwon; Sangwon Byun; Zhen Xiao; Sean Park; Shwu-Yuan Wu; Cheng-Ming Chiang; Byron Kemper; Jongsook Kim Kemper
Journal:  Nat Commun       Date:  2016-07-14       Impact factor: 14.919

5.  Resveratrol modifies biliary secretion of cholephilic compounds in sham-operated and cholestatic rats.

Authors:  Eva Dolezelova; Alena Prasnicka; Jolana Cermanova; Alejandro Carazo; Lucie Hyrsova; Milos Hroch; Jaroslav Mokry; Michaela Adamcova; Alena Mrkvicova; Petr Pavek; Stanislav Micuda
Journal:  World J Gastroenterol       Date:  2017-11-21       Impact factor: 5.742

6.  The HVEM-BTLA Immune Checkpoint Restrains Murine Chronic Cholestatic Liver Injury by Regulating the Gut Microbiota.

Authors:  Yanbo Kou; Xingping Zheng; Liyuan Meng; Mengnan Liu; Shihong Xu; Qiyue Jing; Shenghan Zhang; Hanying Wang; Jinzhi Han; Zhuanzhuan Liu; Yanxia Wei; Yugang Wang
Journal:  Front Immunol       Date:  2022-02-04       Impact factor: 7.561

7.  Postprandial FGF19-induced phosphorylation by Src is critical for FXR function in bile acid homeostasis.

Authors:  Sangwon Byun; Dong-Hyun Kim; Daniel Ryerson; Young-Chae Kim; Hao Sun; Bo Kong; Peter Yau; Grace Guo; H Eric Xu; Byron Kemper; Jongsook Kim Kemper
Journal:  Nat Commun       Date:  2018-07-03       Impact factor: 14.919

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.